Table 1.
Patients’ characteristics
| All | Aged < 65 years | Aged ≥ 65 years | P value | |
|---|---|---|---|---|
| N = 540 | N = 448 | N = 92 | ||
| Age, years | ||||
| Mean (SD) | 52.5 (11.9) | 49.0 (9.55) | 69.9 (4.32) | < 0.001 |
| Sex, n (%) | 0.199 | |||
| Male | 471 (87.2) | 395 (88.2) | 76 (82.6) | |
| Female | 69 (12.8) | 53 (11.8) | 16 (17.4) | |
| ECOG PS, n (%) | 0.383 | |||
| 0 | 309 (57.2) | 262 (58.5) | 47 (51.1) | |
| 1 | 210 (38.9) | 168 (37.5) | 42 (45.7) | |
| 2 | 21 (3.89) | 18 (4.02) | 3 (3.26) | |
| BCLC stage, n (%) | 0.075 | |||
| A | 10 (1.85) | 7 (1.56) | 3 (3.26) | |
| B | 116 (21.5) | 90 (20.1) | 26 (28.3) | |
| C | 414 (76.7) | 351 (78.3) | 63 (68.5) | |
| AFP, ng/ml | ||||
| Median [range] | 188 [7.90;5341] | 267 [8.99;7899] | 44.5 [4.97;1766] | 0.009 |
| AFP ≥ 20 ng/ml | 371 (69.3) | 315 (70.9) | 56 (61.5) | 0.099 |
| Child-Pugh Class, n (%) | 0.827 | |||
| A | 399 (73.9) | 332 (74.1) | 67 (72.8) | |
| B | 138 (25.6) | 113 (25.2) | 25 (27.2) | |
| C | 3 (0.56) | 3 (0.67) | 0 (0.00) | |
| HBV, n (%) | 463 (85.7) | 399 (89.1) | 64 (69.6) | < 0.001 |
| Intrahepatic metastasis, n (%) | 405 (75.0) | 340 (75.9) | 65 (70.7) | 0.355 |
| Number of distant metastatic sites, n (%) | 0.861 | |||
| 1 | 173 (32.0) | 145 (32.4) | 28 (30.4) | |
| 2 | 111 (20.6) | 93 (20.8) | 18 (19.6) | |
| Treatment line of ICI, n (%) | 0.199 | |||
| 1 | 427 (79.1) | 358 (79.9) | 69 (75.0) | |
| 2 | 98 (18.1) | 80 (17.9) | 18 (19.6) | |
| ≥ 3 | 15 (2.78) | 10 (2.23) | 5 (5.43) | |
Categorical values are shown as n (%). Continuous variables are shown as mean (standard deviation) or median [interquartile range]
ECOG PS eastern cooperative oncology group performance status, BCLC stage barcelona clinic liver cancer stage, AFP alpha-fetoprotein, HBV hepatitis B virus, ICI immune checkpoint inhibitor, n, number